mGluR2正向变构调节对精神分裂症额纹状体工作记忆激活的影响
该双盲、安慰剂对照、随机交叉(14天洗脱)试验在26例慢性稳定期精神分裂症患者中评估辅助使用mGluR2正向变构调节剂AZD8529(80mg/日,共3天)对n-back工作记忆任务fMRI反应的影响。AZD8529未产生显著的组平均症状或认知准确性效应,但增加了纹状体(p<0.0001)和前扣带/旁扣带(p=0.002)的n-back fMRI激活。药物-安慰剂对尾状核激活的效应与PANSS阴性症状减分显著相关(r=-0.42,p=0.031)。
要点
- AZD8529未显著改善组平均症状或认知准确性。
- AZD8529增加纹状体及前扣带/旁扣带n-back fMRI激活。
- 尾状核激活药物-安慰剂效应与PANSS阴性症状减分相关。
核心结论
- mGluR2正向调节的fMRI反应与症状减分的个体差异相关,组水平阴性临床结果不应过早终止该机制研究。
研究设计与样本
- 双盲、安慰剂对照、随机交叉(14天洗脱)试点研究,纳入慢性稳定期精神分裂症患者26例进行分析。
- 辅助使用AZD8529 80mg每日共3天,采用3T fMRI评估n-back工作记忆任务中额纹状体区域反应。
主要发现
- AZD8529未产生显著的症状或认知准确性组平均效应。
- AZD8529增加纹状体n-back fMRI激活(p<0.0001)和前扣带/旁扣带激活(p=0.002)。
- 药物-安慰剂对尾状核激活的效应与PANSS阴性症状减分显著相关(r=-0.42,p=0.031)。
临床怎么用
- fMRI反应可作为mGluR2正向调节治疗个体差异的潜在生物标志物进行后续开发。
- 组水平阴性结果不应过早终止对该机制的探索,该机制可能惠及部分精神分裂症患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Negative symptoms and cognitive deficits contribute strongly to disability in schizophrenia, and are resistant to existing medications. Recent drug development has targeted enhanced NMDA function by increasing mGluR2/3 signaling. However, the clinical utility of such agents remains uncertain, and markers of brain circuit function are critical for clarifying mechanisms and understanding individual differences in efficacy. We conducted a double-blind, placebo-controlled, randomized cross-over (14 day washout) pilot study evaluating adjunctive use of the mGluR2 positive allosteric modulator AZD8529 (80 mg daily for 3 days), in chronic stable patients with schizophrenia (n = 26 analyzed). We focused on 3 T fMRI response in frontostriatal regions during an n-back working memory task, testing the hypothesis that AZD8529 produces fMRI changes that correlate with improvement in negative symptoms and cognition. We found that AZD8529 did not produce significant group-average effects on symptoms or cognitive accuracy. However, AZD8529 did increase n-back fMRI activation in striatum (p < 0.0001) and anterior cingulate/paracingulate (p = 0.002). Greater drug-versus-placebo effects on caudate activation significantly correlated with greater reductions in PANSS negative symptom scores (r = -0.42, p = 0.031), and exploratory correlations suggested broader effects across multiple symptom domains and regions of interest. These findings demonstrate that fMRI responses to mGluR2 positive modulation relate to individual differences in symptom reduction, and could be pursued for future biomarker development. Negative clinical results at the group level should not lead to premature termination of investigation of this mechanism, which may benefit an important subset of individuals with schizophrenia. Imaging biomarkers may reveal therapeutic mechanisms, and help guide treatment toward specific populations.
引用
- Wolf DH, Zheng D, Kohler C, et al. Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia. Mol Psychiatry. 2021. PMID: 34667261. doi:10.1038/s41380-021-01320-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。